[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602956":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":36,"locations":44,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":11,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empirical vonoprazan-based therapy","EXPERIMENTAL",null,[13],"Drug: Vonoprazan based ET",{"label":15,"type":16,"description":11,"interventionNames":17},"Susceptibility-guided vonoprazan-based therapy","ACTIVE_COMPARATOR",[18],"Drug: Vonoprazan based SGT",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Vonoprazan based ET","Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Vonoprazan based SGT","Susceptibility testing guided therapy Based onsusceptibility test:Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin quadruple therapy",[15],[30,33],{"name":31,"affiliation":5,"role":32},"Jyh-Ming Liou, MD, PhD","STUDY_DIRECTOR",{"name":34,"affiliation":5,"role":35},"Mei-Jyh Chen, MD, PhD","PRINCIPAL_INVESTIGATOR",[37,41],{"name":34,"role":38,"phone":39,"phoneExt":11,"email":40},"CONTACT","886-2-23123456 Ext. 265427","migichen@ntuh.gov.tw",{"name":42,"role":38,"phone":11,"phoneExt":11,"email":43},"Yu-Chun Huang","nneder34@gmail.com",[45],{"facility":5,"status":11,"city":46,"state":11,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":11},"Taipei","Taiwan","TW",{"type":50,"coordinates":51},"Point",[52,53],121.52639,25.05306,{"lat":53,"lon":52},{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100602956","efficacy-of-vonoprazan-based-rescue-therapy-for-h-pylori-eradication-100602956",false,"NCT07130253","Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","Inclusion Criteria:\n\n1. Helicobacter pylori infected individuals who have failed at least two previous eradication therapies.\n2. Willing to undergo third-line eradication therapy.\n3. Subjects must be 20 years of age or older.\n\nExclusion Criteria:\n\n1. History of gastrectomy.\n2. Individuals unsuitable for the study medication, such as those with a history of allergy or severe adverse reactions to the study drugs, quinolone or fluoroquinolone antibiotics, or women who are pregnant or breastfeeding.\n3. Presence of severe acute or chronic diseases such as renal failure, liver cirrhosis, incurable malignant tumors, or a history of aortic aneurysm or dissection.\n4. Patients with chronic hepatitis (AST or ALT \\> 100 U\u002FL).\n5. Unwillingness to comply with the treatment plan or sign the informed consent form.","ALL","20 Years",{"count":66,"type":67},220,"ESTIMATED","INTERVENTIONAL",[70],"NA","1. This study aims to compare the efficacy of empirical vonoprazan-based therapy versus susceptibility-guided vonoprazan-based therapy for third-line eradication of H. pylori.\n2. We also plan to explore the impact of eradication therapy on gut microbiota, fecal antibiotic resistance, and metabolic parameters before and after treatment.",[73],"HELICOBACTER PYLORI INFECTIONS","NOT_YET_RECRUITING","2025-08-12",{"date":77,"type":78},"2025-08-19","ACTUAL",{"date":80,"type":67},"2025-08-18",{"date":82,"type":67},"2030-06-30",{"name":5,"class":6},1]